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Abstract
Exome sequencing studies in complex diseases are challenged by the allelic heterogeneity, large number and modest effect
sizes of associated variants on disease risk and the presence of large numbers of neutral variants, even in phenotypically
relevant genes. Isolated populations with recent bottlenecks offer advantages for studying rare variants in complex diseases
as they have deleterious variants that are present at higher frequencies as well as a substantial reduction in rare neutral
variation. To explore the potential of the Finnish founder population for studying low-frequency (0.5–5%) variants in
complex diseases, we compared exome sequence data on 3,000 Finns to the same number of non-Finnish Europeans and
discovered that, despite having fewer variable sites overall, the average Finn has more low-frequency loss-of-function
variants and complete gene knockouts. We then used several well-characterized Finnish population cohorts to study the
phenotypic effects of 83 enriched loss-of-function variants across 60 phenotypes in 36,262 Finns. Using a deep set of
quantitative traits collected on these cohorts, we show 5 associations (p,561028) including splice variants in LPA that
lowered plasma lipoprotein(a) levels (P = 1.56102117). Through accessing the national medical records of these participants,
we evaluate the LPA finding via Mendelian randomization and confirm that these splice variants confer protection from
cardiovascular disease (OR = 0.84, P = 361024), demonstrating for the first time the correlation between very low levels of
LPA in humans with potential therapeutic implications for cardiovascular diseases. More generally, this study articulates
substantial advantages for studying the role of rare variation in complex phenotypes in founder populations like the Finns
and by combining a unique population genetic history with data from large population cohorts and centralized research
access to National Health Registers.
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Introduction
After widespread success with genome-wide association studies
(GWAS) of common variants, several studies have recently begun
to identify rare (with ,0.5% allele frequency) and low-frequency
(0.5–5%) variants in complex diseases and traits such as
triglycerides [1], insulin processing [2], bone mineral density [3],
Alzheimer’s disease [4], impulsivity [5], and prostate cancer [6],
some of which confer protection from disease [4]. Protective loss of
function variants that can be tolerated in a homozygote state in
humans are of particular interest as potential safe targets for
therapeutic inhibition. Interestingly, many of these studies that have
discovered rare and low-frequency variants use isolated populations
that have undergone bottlenecks resulting in frequency enrichment
of the associated variants. In contrast to the large number of
extremely rare variants present in out-bred populations, such
bottlenecked populations have a smaller spectrum of rare variation.
This observation has been borne out in examples of Mendelian
disease where, for example, Finns and Ashkenazi Jews have
characteristic high incidence of recessive diseases because of the
enrichment of specific mutations [7,8,9] – in the wider European
population these same diseases are rarer and have mutational
spectra involving a more diverse array of extremely rare mutations.
It has not yet been assessed to which extent these population
structures, so advantageous to Mendelian studies but of little
importance to common variant GWAS, might generally improve
the power to identify low-frequency loss-of-function (LoF) variants
in studies of complex disease.
Finnish Loss-of-Function Variants in Medical Genetics
PLOS Genetics | www.plosgenetics.org 2 July 2014 | Volume 10 | Issue 7 | e1004494
To explore this question, we used exome sequencing to
characterize the allelic architecture of the Finnish population
compared with a set of non-Finnish Europeans (NFEs) from the
United States, Great Britain, Germany and Sweden. We
demonstrate that Finns carry a significant enrichment of low-
frequency (0.5–5%) LoF variation, defined here as nonsense and
essential splice sites that are rare in NFEs. In addition to the isolate
population structure, Finland has nationwide health records that
provide decades of follow-up data that can be linked to
epidemiological studies. The availability of nationwide health
records in a population isolate structure triggered us to study the
impact of low-frequency variants on risk factors and disease
outcomes and their risk factors. The Sequencing Initiative Suomi
(The SISu project) aims to combine these resources and build
knowledge and tools for genome health initiatives. We genotyped
83 LoF variants discovered through our exome sequencing, in
several large well-phenotyped population-based cohorts comprised
of 36,262 Finns and tested for association to 60 quantitative traits
and used data from the 13 disease outcomes assessed using the
National Health Registers. We demonstrate that 5 of these
variants have significant associations with clinically relevant
phenotypes, illustrating the general value of the Finnish population
for the study of low-frequency variants studies in complex as well
as Mendelian diseases. We further confirm two LoF variants that
significantly reduce lipoprotein(a) levels are associated with
protection from cardiovascular disease.
Results
As part of the SISu Project, we assembled 3,000 whole-exome
sequences from Finns in projects including GoT2D, ENGAGE,
migraine, METSIM and the 1000 Genomes Project along with
3,000 whole exome-sequences of NFEs from GoT2D, ESP,
NIMH and 1000 Genomes project using the same data generation
and processing pipelines (Table S1). The raw BAM files from these
projects were compressed and re-processed at the Broad Institute
and variant calling was performed in a unified manner to
minimize potential batch effects. We compared the number and
frequency of variable sites in 3,000 Finns and 3000 NFEs (Fig. 1A)
and observed several expected hallmarks of the isolated bottle-
necked Finnish population history. There was a depletion of
‘singletons’, or variants that were observed only once in 3,000
individuals, in Finns compared to NFEs. An average Finn had 3.7
times fewer singleton variants in these data (binomial P,161026).
On the other hand, there was an excess of low-frequency variants
in Finns versus NFEs (binomial P,161026), collectively suggest-
ing that while most rare variants did not survive the bottleneck, the
variants that did have become substantially elevated in frequency
[10], while the rates of common variation were not different
between Finns and NFEs. All these findings are consistent with an
expected impact of the Finnish population bottleneck.
We then stratified the variants according to their functional
annotations – LoF variants, missense variants and synonymous
variants. We found a higher proportion of LoF variants in Finns
compared to NFEs across the rare and low-frequency allelic
spectrum (Fig. 1A, Table S2) and for missense variants predicted
to be deleterious by PolyPhen2 (Fig. S1). We found a similar
observation when comparing the Finns to an equivalent number of
Swedes (Fig. S2). This is also a direct consequence of the
bottleneck: alleles that are elevated in frequency through the
bottleneck are drawn at random from extremely rare variants in
the parental population, where there is a higher proportion of LoF
variants that arose recently or were kept at low frequencies
because of negative selection. This is clearly demonstrated with the
decreasing proportions of LoF variants with increasing allele
frequencies (Fig. 1B). The observation that LoF variants in the
0.5–5% range are enriched in Finns and our hypothesis that some
of these variants might have health related phenotypic conse-
quences, motivated the targeted association study described below
(Fig. 2).
Despite the reduced overall variation in the isolated population,
the existence of a greater number of low frequency LoF variants
results in an average Finn harboring 0.16 homozygous LoF
variants compared to only 0.095 in an average NFE, driven
primarily by homozygosity in the 0.5 to 5% allele frequency range
(Fig. S3B). These features of the Finnish population have already
been well described as they pertain to Mendelian diseases: many
characteristic ‘‘Finnish founder mutations’’ exist at unusually high
frequencies, even up to 1%, for highly penetrant and reproduc-
tively lethal disorders while such variants are extremely rare or
absent in NFEs [11]. We confirmed with simulations that while
such variants are inevitably pushed to extremely low frequency
after 1,000 or more generations, they can easily persist at
frequencies between 0.1 and 1% up to 100 generations after a
bottleneck (Fig. S4). Table S3 shows a table of a set of Finnish
Disease Heritage (www.findis.org) variants and their population
frequencies. The extent to which such variants contribute to more
common diseases, either through highly-penetrant recessive
subtypes or modest risk to carriers, will correspond to advantages
in rare and low-frequency association studies in isolated popula-
tions.
Given our empirical observations of proportionally more LoF
variants in the 0.5–5% allele frequency range in Finns, we next
conducted a test of this hypothesis that some of the Finnish-
enriched low-frequency LoF variants might have strong pheno-
typic effects. We successfully genotyped 83 low-frequency LoF
variants (protein-truncating nonsense, essential splice site variants
and frameshift variants) enriched in Finns based on their ability to
multiplex in four Sequenom MALDI-TOF genotyping pools
(Table S4). Of these 83 variants, 76 variants were more than 2-fold
enriched and 26 were more than 10-fold enriched.in Finns vs.
NFEs. Three genes (SERPINA10, LPA and FANCM) contained
two LoF variants each; we combined these pairs and tested them
as single composite LoF variants, resulting in a total of 80
independent LoF variants tested in this study. These 83 variants
were genotyped in a total of 36,262 individuals from three
population cohorts: FINRISK [12] (26,245 individuals),
Author Summary
We explored the coding regions of 3,000 Finnish individ-
uals with 3,000 non-Finnish Europeans (NFEs) using whole-
exome sequence data, in order to understand how an
individual from a bottlenecked population might differ
from an individual from an out-bred population. We
provide empirical evidence that there are more rare and
low-frequency deleterious alleles in Finns compared to
NFEs, such that an average Finn has almost twice as many
low-frequency complete knockouts of a gene. As such, we
hypothesized that some of these low-frequency loss-of-
function variants might have important medical conse-
quences in humans and genotyped 83 of these variants in
36,000 Finns. In doing so, we discovered that completely
knocking out the TSFM gene might result in inviability or a
very severe phenotype in humans and that knocking out
the LPA gene might confer protection against coronary
heart diseases, suggesting that LPA is likely to be a good
potential therapeutic target.
Finnish Loss-of-Function Variants in Medical Genetics
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Figure 1. Allele frequency spectrum in Finns and NFEs, demonstrating that Finns have proportionally more deleterious rare and
low-frequency variants. (A) Ratio of the number of LoF, missense and synonymous variants found in Finns versus NFEs with the ratios for LoF
variants highlighted in red text and the ratios for synonymous variants in black. The p-values represent the probabilities of the excess of variable sites
Finnish Loss-of-Function Variants in Medical Genetics
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Health2000 (7,363 individuals) and Young Finns [13] (2,654
individuals).
As these three studies are population-based cohorts, we were
able to assess whether any of the homozygous LoF variants result
in such a severe phenotype that these individuals would not be
able to participate in a population survey for instance, due to
lethality in fetal life of early infancy. Study-wide, there was a
modest excess of homozygotes of the variants (1.23-fold versus
Hardy-Weinberg expectation) arising from within population
substructure. A nonsense variant (Q246X) in the Translation
Elongation Factor, Mitochondrial gene (TSFM) that is present at
1.2% allele frequency in Finns and absent in NFEs, was not found
in a homozygous state in .36,000 Finns (Hardy Weinberg
Equilibrium (HWE) P= 0.0077). This suggests that complete loss
of TSFM might result in embryonic lethality, severe childhood
diseases in humans, or that the individuals might not have been
ascertained by the studies employed, i.e. if the individuals are too
sick to be included in the studies. A lookup of this variant in
another 25,237 Finnish samples in exome chip genotyping data
from the GoT2D studies confirmed that the variant is present at
1.2% in Finns, but again with no homozygotes observed
(combined HWE P=1.661024). Recessive missense variants in
TSFM have been reported to result in mitochondrial translation
deficiency [14,15] and Finnish mitochondrial disease patients from
two families have been identified with compound heterozygosity of
this nonsense variant (each with a different second hit in TSFM)
(personal communication) - lending strong evidence to the
hypothesis that complete loss of this gene is not tolerated in
humans. Neither did we observe strong associations for the TSFM
Q246X heterozygotes across major diseases (Table S5).
Several other LoF variants occur in genes where recessive
mutations have been noted to cause severe Mendelian diseases
from the Online Mendelian Inheritance in Man database (OMIM)
[16]. For instance, the Fanconi anemia complementation group M
gene (FANCM) was initially discovered in one family with Fanconi
anemia [17], but we did not observe any deficit of homozygous
LoFs in FANCM from our dataset (expected = 5, observed= 7),
which we would typically observe for a disease causing recessive
Figure 2. Study design figure for the project. The analysis was performed from an initial set of exome sequences from Finns and NFEs, as well as
the selection and survey of the 83 LoF variants across 60 quantitative traits and 13 disease categories.
doi:10.1371/journal.pgen.1004494.g002
in Finns occurring by chance. The p-values in red represent the probabilities for the LoF variants, the p-values in blue represent the probabilities for
the missense variants and the p-values in black represent the probabilities for the synonymous variants. (B) Percentage of variants that are LoF across
the allele frequency spectrum, with the numbers indicating the percentage of LoF variants in Finns versus NFEs. The p-values represent the p-values
from the hypergeometric test of whether the ratio of LoF variants differ from the ratio of synonymous variants in Finns compared to NFEs.
doi:10.1371/journal.pgen.1004494.g001
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variant. Furthermore, examination of the hospital discharge
records did not provide any evidence for blood diseases, increased
cancer events or any other chronic diseases in these individuals
with homozygous LoFs in FANCM. We also had blood counts for
two homozygote individuals. Both of them had normal hemoglo-
bin, erythrocyte size and counts as well as leukocyte and
thrombocyte counts. Singh et al. reported that the initial case
that led to the association of FANCM with Fanconi anemia also
harbor biallelic, functional mutations in FANCA, a well-
established Fanconi anemia gene [18]. Our findings in this study,
combined with the findings by Singh et al. do not support the
hypothesis that FANCM is a Fanconi anemia gene but rather
suggest that the initial FANCM association was not causative. In
addition to FANCM, we further evaluated evidence for two other
genes COL9A2 and DPYD that were previously implicated in
other Mendelian diseases (Supplementary Methods).
The FINRISK cohort had collected 60 biochemical and
physiological quantitative measurements of cardiovascular or
immunologic relevance (Table S6), some of which are highly
correlated. We tested the 80 variants across the 60 traits and
report from this initial screen all associations with p,261024 –
that is, a value where we would expect only one chance
observation in the entire study. In total, we observed 41
associations that exceeded this significance threshold (Table 1),
far beyond the expected. If the phenotype was available in the
Young Finns and Health 2000 cohorts, replication was attempted
for these initial scan hits and significant associations are
highlighted below when the combined p-value was smaller than
a conservative study-wide Bonferroni-corrected threshold of 0.05/
(80*60) = 161025.
Three of these association have been previously reported and
represent positive controls for our approach: a strong association
for the 2 splice variants (c.4974-2A.G and c.4289+1G.A) in the
Lipoprotein(a) gene (LPA) with lipoprotein(a) measurements in
plasma (Pdiscovery = 2.17610
281, Pdiscovery+replication = 1.53610
2117,
combined b^=20.64 or 28.77 mg/dL per allele, Table S7), the
W154X variant in Fucosyltransferase 2 (FUT2) with increased
Vitamin B12 levels [19] (b^=0.2, P= 3.7610226 or 43 pg/mL per
allele, Table S8) and the R225X variant in the Citrate Lyase Beta
Like gene (CLYBL) with decreased Vitamin B12 levels [20] (b^=
20.2, P = 1.861025 or 243 pg/mL per allele, Table S9) [21].
The boxplots for these associations are shown in Fig. S5.
In addition to a strong correlation between circulating
lipoprotein(a) levels and cardiovascular disease, it has been
previously reported that genetic variants that elevate circulating
lipoprotein(a) levels are cardiovascular risk factors [22,23]. The
converse, critical for evaluation of the therapeutic hypothesis of
inhibition, that lowering lipoprotein(a) levels can confer cardio-
vascular protection has not yet been evaluated. With access to
National Health Records, we utilized the strong lipoprotein(a)
lowering variants discovered here to evaluate the impact of
lipoprotein(a) lowering via Mendelian randomization. Using a Cox
proportional hazards model for incident cardiovascular disease in
these cohorts (adjusted for age, gender and therapies), the
composite LPA variant was found to protect against coronary
heart disease (Hazard Ratio HR=0.79, P= 6.761023), demon-
strating that lowering lipoprotein(a) levels are likely to confer
protection for cardiovascular diseases. We adjusted the association
for the composite LPA variant with a previously published risk
variant (rs3798220) [22], but observed a similarly protective effect
(N= 18,270, HR=0.79, P = 0.014), suggesting that the splice
variants are independent from the previously reported risk variants
in LPA.
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We confirmed this finding using three independent non-Finnish
datasets: an early onset myocardial infarction dataset of 18,000
individuals and two studies from the Estonian Biobank (4,600 and
7,953 individuals respectively), which collectively replicated the
observation that the LPA variants confer cardioprotective effect
(OR=0.87, P= 0.016). After meta-analyzing all the datasets, the
final odds ratio was found to be 0.84 (P= 361024, Fig. 3). We
found 227 individuals who are homozygous or compound
heterozygous for the two LPA splice variants with no evidence
for increased morbidity or mortality based on National Health
Records. This suggests that reduction of lipoprotein(a) is well-
tolerated and might constitute a potential drug target for
cardiovascular diseases. A survey across other diseases showed
potential association between the LPA variants with acute
coronary disease and myocardial infarction but not Type 2
Diabetes (Table S10). In addition, we surveyed the LPA variants
across other cardiovascular risk factors and observed that the LPA
variants were associated with mildly increased glucose levels but
not high-density lipoproteins (HDL), low-density lipoproteins
(LDL) or triglycerides (Table S11).
In addition, we observed novel associations for the FGL1,
MS4A2 and ATP2C2 variants. The 1-bp c.545_546insA frame-
shift in the Fibrinogen-like 1 gene (FGL1) was associated with
increased D-dimer levels (b^=0.21, P= 6.161026 or 52.23 ng/mL
per allele, Table S12). D-dimers are products of fibrin degradation
and their concentration in the blood flow is clinically used to
monitor thrombotic activity. The role of FGL1 in clot formation
remains unclear: although FGL1 is homologous with fibrinogen, it
lacks the essential structures for fibrin formation, with one study
suggesting its presence in fibrin clots [24]. In addition, given prior
links between variants associated with D-dimer levels and stroke,
we utilized the same Mendelian randomization approach as for
LPA above and found a nominally significant association between
FGL1 c.545_546insA and increased risk of ischemic stroke
(OR=1.32, P = 0.024). If replicated, this would be consistent
with modest risk increase for stroke that other variants associated
to circulating D-dimer levels, such as reported for variants in
coagulation Factor V, Factor III and FGA [25].
We found suggestive associations for the c.637-1G.A splice
variant in the membrane-spanning 4-domains, subfamily A,
member 2 gene (MS4A2) with triglycerides (Pdiscovery = 7.80610
25,
Pdiscovery+replication = 1.31610
26, b^=0.14 or 0.14 mmol/L per
allele, Table S13). This observation is consistent with our
previously published study of 631 individuals in the DILGOM
subset of FINRISK showing that whole blood expression of
MS4A2 was strongly negatively associated with total triglycerides
(b^=21.62, P= 2.1610227, Fig. S6) [26] and a wide range of
systemic metabolic traits [27]. A similar but insignificant trend was
observed in 15,696 individuals from the D2D2007, DPS,
FUSION, METSIM and DRSEXTRA cohorts (b^=0.04,
P = 0.32). The MS4A2 gene encodes the b-subunit of the high
affinity IgE receptor, a key mediator of the acute phase
inflammatory response.
The c.2482-2A.C splice variant in the ATPase Ca++
Transporting Type 2C Member 2 gene (ATP2C2) was associated
with increased systolic blood pressure (Pdiscovery = 1.25610
25,
Pdiscovery+replication = 1.3610
26, b^=0.12 or 2.13 mmHg per allele
(an association that is undisturbed by correction for lipid lowering
medication (b^=0.12, P= 1.7561025) or blood pressure lowering
medication (b^=0.13, P= 1.361025), Table S14). Based on its
structure, ATP2C2 is predicted to catalyze the hydrolysis of ATP
coupled with calcium transport. Interestingly, the ATP2C2
c.2482-2A.C variant is also significantly associated to several
highly correlated immune markers, such as granulocyte colony-
stimulating factor (b^=0.26, P= 6.9861027), interleukin-4
(b^=0.27, P= 2.4861026), interferon-c (b^=0.26, P= 3.2461026)
and interleukin-6 (b^=0.25, P= 4.5861026).
Discussion
The empirical data of this study sheds light on an active debate
in population genetics theory whether or not bottlenecked
populations have an excess burden of deleterious alleles.
Lohmueller et al. first observed that there were proportionally
more deleterious variants in European American individuals
compared to African American individuals [28]. They performed
a series of forward simulations to demonstrate that such an
observation is consistent with an Out-of-Africa bottleneck
experienced by the European populations from which the
European-American individuals descend, and illustrated that
bottlenecked populations are likely to accumulate a higher
proportion of deleterious alleles. A recent study by Simons et al.
showed conflicting results suggesting that there are similar burdens
of deleterious alleles in Europeans and West Africans and that
demography is unlikely to contribute to the proportions of
deleterious alleles in human populations [29].
The comparison of Finns, with a well-documented bottleneck,
with non-Finnish Europeans here provides strong empirical data
on these questions. While the distribution of common alleles, both
synonymous and non-synonymous, is as expected unchanged by
the bottleneck, when exploring the rare and low-frequency allelic
spectrum where the Finns and NFEs demonstrate distinct
distributions, we indeed observe a significant excess of deleterious
variants in the Finns – despite the considerable deficit in variable
sites in the population overall. This suggests that negative selection
has had insufficient time to suppress the frequency of deleterious
alleles dramatically elevated in frequency through the founding
bottleneck, an observation that generalizes the intuitive under-
standing of the existence of characteristic and unusually common
Mendelian recessive disorders in Finland. However, we note that
while we observe a strong influence of the founding bottleneck, the
observed results, particularly the proportional enrichment of rare
deleterious variants, are also influenced by other elements in the
unique history of the Finnish population and will not necessarily
apply to all populations influenced by a bottleneck.
This excess of presumably deleterious variants motivated the
subsequent association study and indeed, the absence of homo-
zygotes at TSFM (contemporaneously identified as an early-onset
mitochondrial disease gene) suggests that low-frequency variants in
Finns, beyond those already identified in Mendelian disease, do
include more unusually strong acting alleles than in non-founder
populations. In this study, both replicated results and novel
associations demonstrate the association of low-frequency LoF
variants with various complex traits and diseases. In addition, we
discovered a novel cardiovascular protective effect from splice
variants in the LPA gene, suggesting that knocking down levels of
circulating lipoprotein(a), or Lp(a), can confer a protection from
cardiovascular diseases. Given that we detected numerous
individuals in these adult population cohorts, healthy and in the
expected Hardy-Weinberg proportions, carrying a complete
knockout of LPA (homozygous or compound heterozygous for
the 2 splice variants), this suggests that knocking out the gene in
humans does not result in severe medical consequences. As such,
this study provides data suggesting that LPA may be an effective
target for therapeutic purposes.
As more Finnish samples are being sequenced, these enriched
variants can also be imputed with high precision to the large
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number of existing samples with array-based GWAS genotypes.
This advantage is likely to be more pronounced for the much
larger pool of missense variation – while one can presume all LoF
variants in a gene might have a comparable effect on phenotype
(and thereby burden tests of LoF variants in an out-bred sample is
not at a great disadvantage compared to isolated populations), it is
evident that many rare missense variants within the same gene will
not all have the same impact on gene function. Thus the ability to
assess single low-frequency variants conclusively, especially since
they will include an excess of damaging variants enriched through
a bottleneck, rather than perform burden tests on heterogeneous
sets of extremely rare variants, will offer substantial ongoing
advantage to isolated population studies as indicated by these and
other recent findings.
Materials and Methods
All research involving human participants have been approved
by the Hospital District of Helsinki and Uusimaa Coordinating
Ethical Committee, and all clinical investigation was conducted
according to the principles expressed in the Declaration of
Helsinki.
Exome sequencing quality control, annotation and
filtering
Raw Binary Sequence Alignment/Map (BAM) files from the
various projects were jointly processed at the Broad Institute and
joint variant calling was performed on all exomes to minimize
batch differences. Functional annotation was performed using the
Variant Effect Predictor (VEP v2.5) tool from Ensembl (http://
useast.ensembl.org/info/docs/tools/vep/). We modified it to
produce custom annotation tags and additional loss-of-function
annotations. The additional annotations were applied to variants
that were annotated as STOP_GAINED, SPLICE_DONOR_-
VARIANT, SPLICE_ACCEPTOR_VARIANT, and FRAME_-
SHIFT and the variants were flagged if any filters failed. A loss-of-
function variant was predicted as high confidence if there is one
transcript that passes all filters, otherwise it is predicted as low
confidence. In our genotyping study, we had used loss-of-function
variants that were predicted to be high confidence. For quality
control, we required all variants to pass the basic GATK filters and
required all genotypes to have a quality score of $30, read depth
of $10 and allele balance of between 0.3 and 0.7 for heterozygous
calls and ,0.1 for homozygous calls. Allele counts and frequencies
were calculated within the 3,000 individuals for Finns and NFEs
respectively.
Detecting amount of substructure in the Finnish and NFE
exomes
To estimate the amount of substructure or homozygosity by
descent, we fitted a regression model on all coding variants with
the intercept set to 0, where q is the allele frequency of the
alternate allele and FST is the proportion of allelic variance
explained by population structure. Here we fit FST to capture the
empirical departure from Hardy-Weinberg equilibrium arising
from population substructure to insure this is not creating the
observed difference between Finnish and NFE samples:
Number of homozygotes
Number of individuals
~FST qz(1-FST )q
2
Using the whole-exome sequencing data for the 3,000 NFEs, we
estimated the parameters:
E(FST )~0:00898
1{E(FST )~0:991
FST~
E(FST )
1{E(FST )
~0:91%
Using the whole-exome sequencing data for the 3,000 Finns, we
estimated the parameters:
E(FST )~0:00675
1{E(FST )~0:993
FST~
E(FST )
1{E(FST )
~0:68%
Figure 3. Forest plot for the LPA splice variants with cardiovascular diseases. The cardiovascular diseases were defined as coronary heart
disease (CHD), ischemic heart disease (IHD), heart failure (HF) or myocardial infarction (MI) from the various cohorts.
doi:10.1371/journal.pgen.1004494.g003
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As shown, there is little substructure in the 3,000 Finns compared
to the 3,000 NFEs, given that the estimates for FST are similar in
both populations.
Variant selection for genotyping
All frameshifts and loss-of-function single nucleotide variants
with allele frequencies of 0.5–5% in Finns and at least 2-fold
enriched in Finns compared to NFEs were selected for
genotyping. To minimize the false positives in our variant
selection, we performed Fisher’s Exact Test for each variant
between two independent NFE datasets and kept variants whose
allele frequencies were highly concordant between the two NFE
datasets (P.161025). The high concordance between the allele
frequencies in two independent NFE datasets ensures that the
variants are unlikely to arise from alignment or sequencing
artifacts and that these variants are unlikely to reside in a region
of the exome that is difficult to sequence or genotype, which can
result in highly variable allele frequencies from different
experiments.
Sequenom genotyping
Genotyping was performed using the iPLEX Gold Assay
(Sequenom Inc.). Assays for all SNPs were designed using the
eXTEND suite and MassARRAY Assay Design software version
3.1 (Sequenom Inc.). Amplification was performed in a total
volume of 5 mL containing ,10 ng genomic DNA, 100 nM of
each PCR primer, 500 mM of each dNTP, 1.256 PCR buffer
(Qiagen), 1.625 mM MgCl2 and 1 U HotStar Taq (Qiagen).
Reactions were heated to 94uC for 15 min followed by 45 cycles at
94uC for 20 s, 56uC for 30 s and 72uC for 1 min, then a final
extension at 72uC for 3 min. Unincorporated dNTPs were SAP
digested prior to iPLEX Gold allele specific extension with mass-
modified ddNTPs using an iPLEX Gold reagent kit (Sequenom
Inc.). SAP digestion and extension were performed according to
the manufacturer’s instructions with reaction extension primer
concentrations adjusted to between 0.7–1.8 mM, dependent upon
primer mass. Extension products were desalted and dispensed onto
a SpectroCHIP using a MassARRAY Nanodispenser prior to
MALDI-TOF analysis with a MassARRAY Analyzer Compact
mass spectrometer. Genotypes were automatically assigned and
manually confirmed using MassARRAY TyperAnalyzer software
version 4.0 (Sequenom Inc.). The genotyped variants were then
checked for concordance in allele frequencies with the exome
sequencing data.
Phenotyping
Data on disease status from National Health registers (Hospital
Discharged Registers maintained by THL (Institute for Health
and Welfare, Finland), Cause of Death Register, Statistics Finland
and Prescription Medication Register, THL) for FINRISK,
Health2000 and the Young Finns Study participants of this study
were collected and curated. A description of each cohort is
provided in the Supplement.
Analyses of RNA sequencing data
To analyze the effects of the LoF variants on gene expression,
we used RNA sequencing data from two major studies: the
GEUVADIS project [30] with RNA sequencing data from
lymphoblastoid cell lines of 462 individuals participants from the
1000 Genomes Project [31]), and the GTEx project with RNA-
sequencing data from a total of 175 individuals with 1–30 tissues
each (http://www.broadinstitute.org/gtex/) [32]. The processing
of the GEUVADIS data and the methods for allele-specific
expression analysis are described in Lappalainen et al. [30] and the
GTEx data were analyzed using similar methods. Allele-specific
expression analysis was used primarily to capture nonsense-
mediated decay. Additionally, to assess whether LoF variants lead
to decreased exon expression levels overall or for individual exons,
we calculated an empirical p-value for each exon of all the LoF
genes with respect to all other exons genome-wide, denoting the
proportion of all exons where carriers of the LoF variants are more
extreme than in the each studied exon in LoF variant genes. The
analyses were performed separately in each studied tissue:
lymphoblastoid cell lines from the GEUVADIS data and nine
tissues from the GTEx data. The significance threshold after
correcting for the total number of tested exons across all tissues is
0.05/1070= 4.6761025.
Statistical analyses and methods
Inverse rank-based normalization was performed on the
quantitative measurements in males and females separately,
with linear regression residuals using age and age2 as covariates.
Linear regression was then performed on the normalized Z-
scores using R to obtain the statistics for the associations. We
tested the correlations between the quantitative measurements
and disease outcomes using two one-tailed t-tests to assess the
significance of observing higher levels of the quantitative
measurements in cases (individuals with the disease outcomes)
versus controls (individuals without the disease outcomes), as
well as lower levels of the quantitative measurements in cases
versus controls. To test the association of the variants with the
prevalent disease outcomes, we performed a logistic regression
in R to obtain the reported statistics. In addition, a Fisher’s
Exact Test on the homozygous counts in cases and controls were
performed to test for association with the homozygotes. The
results for the LPA with cardiovascular disease association from
MIGen ExA and the Estonian Biobank were meta-analyzed
using METAL [33] and the combined results with FINRISK
were obtained using the Fisher’s Combined P method with 4
degrees of freedom.
Associations between MS4A2 c.637-1G.A, gene
expression and triglycerides
We fit a linear model in which the log2-normalised gene probe
expression of individual i was regressed on the LoF genotype,
which was encoded as Xi=0, 1 or 2 for the LoF genotypes 2/2,
+/2 or +/+ respectively and association analysis of MS4A2 gene
expression and triglycerides was performed as previously reported
[26]. Briefly, we used a multivariate linear regression adjusted for
age, gender, and use of cholesterol or blood pressure lowering
medication. We further tested for association between MS4A2
c.637-1G.A and triglycerides using a 2-sided t-test.
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Figure S1 Ratio of the number of missense variants predicted by
PolyPhen2 found in Finns versus NFEs. (A) The ratios for
probably damaging missense variants highlighted in red text and
the ratios for benign missense variants in black. The p-values
represent the binomial probabilities of the variants being enriched
in Finns and similarly, the p-values in red represent the
probabilities for the probably damaging missense variants and
the p-values in black represent the probabilities for the benign
missense variants. (B) Percentage of variants that are missense
variants across the allele frequency spectrum.
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Figure S2 Allele frequency distribution in 3,000 Finns compared
to 3,000 Swedes. The ratios for LoF variants highlighted in red
text and the ratios for synonymous variants in black.
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Figure S3 Distribution of LoF variants per individual. (A) Number
of LoF variants in an average Finn vs NFE individual. (B) Number of
homozygous LoF variants in Finns vs NFEs per individual.
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Figure S4 Simulations for a set of variants (ranging from 1%
to 5% allele frequencies) with complete recessive lethality. The
red line indicates the expected allele frequencies in present-day
Finns (where the Finnish bottleneck occurred ,100 generations
ago) and the blue line indicates the expected allele frequencies
in Finns 1,000 generations after the Finnish bottleneck, similar
to the out-of-Africa bottleneck which occurred .1,000 gener-
ations ago.
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expression.
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the different studies was performed on the exome chip genotyping
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(P,161023) are shaded in blue and the rows with significant
association (P#0.05) between the variant and disease status
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levels of the biomarker and disease status (P,161023) are shaded
in blue and the rows with significant association (P#0.05) between
the variant and disease status (allelic or homozygous tests) are
highlighted in red text.
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levels of the biomarker and disease status (P,161023) are shaded
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highlighted in red text.
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between the levels of the biomarker and disease status (P,
161023) are shaded in blue and the rows with significant
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